After chat with FDA, ImmunoGen delays pivotal top-line data on blood cancer ADC to 2024

After chat with FDA, ImmunoGen delays pivotal top-line data on blood cancer ADC to 2024

Submitted by admin on August 31, 2022 - 10:31am
Source: 
Fierce Biotech
News Tags: 
Immunogen
antibody drug conjugate
pivekimab sunirine
blood cancer
Headline: 
After chat with FDA, ImmunoGen delays pivotal top-line data on blood cancer ADC to 2024
snippet: 

ImmunoGen is rethinking the pivotal program for blood cancer antibody-drug conjugate (ADC) pivekimab sunirine.

Do Not Allow Advertisers to Use My Personal information